Funding RisksKey risks include failed or equivocal trial results, unforeseen safety or tolerability issues, meaningful delays to expected timelines, and inability to sufficiently fund operations.
Safety And EfficacyCurrently uncertain on the safety and efficacy of Assembly's programs including ABI-5366 and ABI-6250.
Valuation ConcernsPreviously removed price target for ASMB shares as the valuation was based on the projected revenue from its HBV core inhibitor program.